Date: 2014-10-24
Type of information: Grant
Company: Oryzon Genomics (Spain)
Investors: Ministry of Economy and Competitiveness of the Spanish Government (Spain)
Amount: € 1.1 million
Funding type: grant
Planned used: A substantial part of the Grant will be devoted to finance the Clinical Phase 1 studies in Acute leukemia of Oryzon’s LSD1 inhibitor that is nearing the end of preclinical development. Clinical activities in Spain will be developed by the hospital Valle de Hebron in Barcelona.
Others: * On October 24, 2014, Oryzon announced that it was awarded a 36 month 1.103.602 Euros grant under the INNPACTO-2012 Collaborative Program from the Ministry of Economy and Competitiveness of the Spanish Government.
Therapeutic area:
